PhD Scientific Days 2025
Budapest, 7-9 July 2025
Cardiovascular Medicine and Research II.
Characteristics and outcomes of patients with heart failure and history of malignancy: data from Swedish Heart Failure Registry
Előadó neve
Dr. Sayour V. Nabil
Neptun code
ECPETN
Előadó munkahelye
Department of Pharmacology and Pharmacotherapy
Előadó telefonszáma
+36704179180
Előadó e-mail címe
sayour.nabil@gmail.com
Az előadás címe
Characteristics and outcomes of patients with heart failure and history of malignancy: data from Swedish Heart Failure Registry
Szerző(k) neve és munkahelye
Nabil Viktor Sayour1, Pietro Ameri2, Paolo Costa2, Lina Benson3, Davide Stolfo3, Charlotta Ljungman4, Javed Butler5, Stefan D Anker6, Nicolas Girerd7, Kalliopi Keramida8, Gerasimos Filippatos9, Lars H Lund10, Felix Lindberg3, Gianluigi Savarese3
1: Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary
2: Department of Internal Medicine, University of Genova, Genova, Italy
3: Department of Clinical Sciences and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden
4: Department of Molecular and Clinical Medicine, University of Gothenburg, Goteborg, Sweden
5: Department of Cardiology, Baylor College of Medicine, Houston TX, United States of America
6: Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany
7: Université de Lorraine, Centre d'Investigation Clinique-Plurithématique CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, France
8: Department of Cardiology, General Anti-Cancer Oncological Hospital Agios Savvas, Athens, Greece
9: Department of Cardiology, National and Kapodistrian University of Athens,School of Medicine, Attikon University Hospital, Athens, Greece
10: Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Bemutatás módja
Szóbeli
Szekció
Cardiovascular Medicine and Research II.
Language of the presentation
English
Preferred session
Cardiovascular Medicine and Research
Összefoglaló szövege
Introduction: Whether a history of malignancy affects heart failure (HF) management and prognosis is unclear. In HF randomized controlled trials (RCTs), enrolment has been limited to patients with a cancer diagnosis at least 2 years before screening.
Aims: To investigate the clinical profile, HF treatment patterns, and outcomes of patients with a history of cancer of >2 years.
Methods and Results: Among 53,314 patients included in the Swedish HF Registry between 2000 and 2020, 9,066 (17%) had previous cancer (diagnosed >2 years prior to index date), most frequently of prostate (26%), breast (15%), colon (11%), and hematologic system (11%). Previous cancer was associated with older age, female sex, comorbidity burden, and less likely specialized follow-up. Over a median follow-up of 2.4 (min-max: 0.0-5.0) years, mortality rates were 24 [95%CI 23-25] and 18 [95%CI 18-19] per 100 subject-years in patients with vs without previous cancer, respectively, with cancer accounting for 16% vs 5.6% of deaths. Prior malignancy was independently associated with higher risk of all-cause death (adjusted HR 1.14, 95%CI 1.11-1.18), non-cardiovascular (non-CV) death (adjusted HR 1.38, 95%CI 1.31-1.44), and first all-cause hospitalization (adjusted HR 1.11, 95%CI 1.09-1.14). The risk of non-CV death declined with increasing time from cancer diagnosis. In patients with HF and reduced EF, history of cancer was associated with less frequent use of mineralocorticoid receptor antagonists, triple pharmacotherapy, and HF devices.
Conclusions: Previous cancer was common among patients with HF, and it was associated with comorbidity burden, non-CV outcomes and, in HFrEF, with lower use of guideline-recommended therapies.
Funding: EKÖP-2024-182 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund
University
Semmelweis University
Supervisor
Zoltán V. Varga
Publication of my abstract
I do not give consent to the publication of my abstract on the website of the congress.
phd.section.field
in doctoral studies after complex exam (PhD)
Kind
Szabad
Status
elfogadva
Accepted presentation method
szóbeli
Előadás fájl jóváhagyás
nem rendelkezett róla
Előadó
6116
Start
16:15
End
16:30